PMID- 19936821
OWN - NLM
STAT- MEDLINE
DCOM- 20100623
LR  - 20211020
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Linking)
VI  - 257
IP  - 4
DP  - 2010 Apr
TI  - Parenthood and immunomodulation in patients with multiple sclerosis.
PG  - 580-3
LID - 10.1007/s00415-009-5376-z [doi]
AB  - Little is known about the influence of immunomodulation on parenthood, in 
      particular paternity in multiple sclerosis (MS). The objective was to determine 
      whether there is an increased risk for pregnancies initiated by MS-parents under 
      disease modifying therapies (DMT). We investigated the clinical outcome of 
      pregnancies fathered by MS-patients under DMT by nationwide questionnaire and 
      within our own outpatient clinic. Additionally, we compared the birth weight of 
      children from MS-fathers exposed to DMT, MS-mothers without DMT, MS-mothers under 
      interferon-beta (IFN beta) at the time of conception and healthy controls (HCs). 
      DMT was reported for 32 paternities of 46 children; 30 under IFN beta, 12 under 
      glatiramer acetate, 2 under natalizumab, 1 under methotrexate and 1 under 
      combined azathioprine- and IFN beta-1b-treatment. Six (13%) pregnancies ended in 
      early spontaneous abortions; of the 40 children of MS-fathers under DMT, 2 (5%) 
      were preterm, 1 (2.5%) had a spinal lipoma and 3 (7.5%) had moderate hip 
      dysplasia, of whom 2 were siblings whose mother had severe hip dysplasia. Mean 
      birth weight of newborns from MS-fathers under DMT was not significantly reduced 
      compared to HCs. Comparing birth weight of newborns of MS-mothers versus 
      MS-fathers, we found a significant difference to the disadvantage of MS-mothers 
      with or without IFN beta-treatment. No statistical difference in birth weight of 
      IFN beta-exposed versus untreated MS-mothers was observed. Despite the small 
      numbers, our available data suggest safe paternity by MS-patients. IFN 
      beta-treatment of mothers does not seem to have an impact on birth weight, 
      however, MS may contribute to a reduced birth weight.
FAU - Hellwig, Kerstin
AU  - Hellwig K
AD  - Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 
      Gudrunstrasse 56, 44791, Bochum, Germany. k.hellwig@klinikum-bochum.de
FAU - Haghikia, Aiden
AU  - Haghikia A
FAU - Gold, Ralf
AU  - Gold R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091121
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Adult
MH  - Birth Weight/drug effects
MH  - Databases, Factual/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Immunologic Factors/*therapeutic use
MH  - Infant
MH  - Male
MH  - Multiple Sclerosis/*drug therapy/immunology
MH  - Outcome Assessment, Health Care
MH  - *Parent-Child Relations
MH  - Pregnancy
MH  - Prenatal Exposure Delayed Effects/immunology/physiopathology
MH  - Surveys and Questionnaires
EDAT- 2009/11/26 06:00
MHDA- 2010/06/24 06:00
CRDT- 2009/11/26 06:00
PHST- 2009/04/08 00:00 [received]
PHST- 2009/10/30 00:00 [accepted]
PHST- 2009/06/04 00:00 [revised]
PHST- 2009/11/26 06:00 [entrez]
PHST- 2009/11/26 06:00 [pubmed]
PHST- 2010/06/24 06:00 [medline]
AID - 10.1007/s00415-009-5376-z [doi]
PST - ppublish
SO  - J Neurol. 2010 Apr;257(4):580-3. doi: 10.1007/s00415-009-5376-z. Epub 2009 Nov 
      21.